Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : gensia(gnsa) -- Ignore unavailable to you. Want to Upgrade?

To: mogo who wrote (59)	7/9/1998 5:26:00 PM
From: GenJackripper	Respond to of 71

mogo: You, mogo, and other lurkers interested in GNSA, would be well advised to spend a little time with GNSA's Home Page. You can access it by going back to the page before this one and clicking on Profile thereon below where you inputted the company's stock symbol to access this thread for GNSA. When GNSA's Profile page appears, scroll down to Home Page under Company Links. When GNSA's Home page appears, begin with the company's profile and continue from there through its other aspects. The Company Description below Company Links here on SI's Profile page for GNSA is, by now, ancient history, largely inapplicable to the extant and future GNSA and therefor misleading, IMO. You should also contact GNSA's IR person, Laurie Little, @ (800) 729-9991, Ext. 4879, and request an investor kit. Since February 1997, when Donald E. Panoz (DEP) assumed the Chairmanship, GNSA has been transitioning from a research and development oriented biotechnical company to a specialty pharmaceutical company. DEP had interested a long-time business acquaintance and friend, Carlo Salvi (CS), the Chairman of "Sicor" in joining forces with him in this endeavor and Gensia became Gensia Sicor. As a result, CS is GNSA's largest individual shareholder (38.5%) and, when DEP became Chairman, CS became a director and Chairman of GNSA's Executive Operating Committee. In November 1997, DEP also assumed the duties of President and CEO and CS became an Executive Vice Prsident of GNSA. Mr. Panoz comes to the tiller @ GNSA having been a founder of both Elan Corporation (NYSE: ELN) and Mylan Laboratories (NYSE: MYL). While I do not believe DEP regards himself as a maven of the biotechnical industry, when it comes to the pharmaceutical business, it is definitely not DEP's "first day." Look at the coverages for ELN and MYL, then look at the numbers covering GNSA. If you look at the Recent Quarter Results Table at the bottom of GNSA's Profile page here on SI, you'll note that when DEP assumed its chairmanship, GNSA was losing almost $13 million per month in 1Q97. Due to his reorganizational, restructuring, and cost-cutting efforts over the ensuing five quarters, that hemorrhaging has been staunched and it is anticipated that GNSA could report profitability for, perhaps, I believe, the first time in its history, if not in 2Q98 then in 3Q98. FY98 is expected to finish in the black. When profitability is a "fact accompli", I suspect DEP, now armed with something to talk about, will be hitting the bricks with GNSA's dog and pony show to speak to The Street, many of whom already know who DEP is and what he's done. A few more investors may then get to know what the new Gensia Sicor is all about. In the meantime, you might want to monitor Free Edgar or Edgar Online this week and next for substantiation of recent insider buying.

To: mogo who wrote (59)	7/9/1998 6:18:00 PM
From: GenJackripper	Read Replies (1) \| Respond to of 71

Some tidbits: (as of 6/15/98) 1. GNSA is a manufacturer and marketer of both bulk and finished pharmaceuticals, 90% of which are generics. 2. Of the 10 FDA applications submitted in FY97, GNSA has received approvals for 9. 3. GNSA had submitted ten additional applications thus far in FY98, four of which, I believe, were for oncology injectables. 4. Gensia Sicor Pharmaceuticals, Inc. (GSPI) had a total of 36 products in development (19 Oncology, 7 Cardiovascular, 10 Specialty) whose 1997 market size (Source: IMS) totalled $4.3 billion. 5. Historically, given time, GNSA's market penetration or share has ranged (depending on the product) from 15% to 40%. 6. A year ago, GNSA received FDA approval to be the supplier to SangStat Medical (OTC: SANG) of bulk cyclosporine (1997 market size: $1.3 billion). Persons receiving organ transplants must take this drug for the rest of their lives to prevent rejection. SANG is awaiting FDA approval to market cyclosporine, an approval that is expected in 3rd or 4th quarter 1998. 7. If you'd like to see what impact that approval will have for SANG, see the Inside Wall Street feature (Page 188) of the 6/22/98 issue of Business Week. Your local library should have back issues. It should mean buco bucks on the bottom line for GNSA as well. 8. GNSA began 1997 ranking 21st among providers of pharmaceuticals to Mexico's populace through its social security system and ended the year ranking in 8th place. About 80% of pharmaceuticals purchased in Mexico by its populace are obtained via the social security system.